Another case of PML hits the MS drug Tysabri
PML is a rare demylinating disease that occurs in 6 per 10 million patients. This is the third case that is associated with Tysabri. Investors are not happy.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Evidence-based medicine vs. clinical judgment: a medical student’s perspective
-
The controversy over Maintenance of Certification for grandfathered physicians
-
How hindsight bias distorts clinical medicine
-
How the new DOT ruling on food allergies threatens air travel safety
-
Why hormonal shifts make traditional dieting ineffective for midlife women [PODCAST]
-
The psychology of hero worship: When admiration overrides reason
-
Past 6 Months
-
The dangers of vertical integration in health care
-
Why does sex work seem like a more viable path than medicine in 2026?
-
The 9 laws of health care quality: Why metrics miss the point
-
Politics and fear have replaced science in U.S. pain management [PODCAST]
-
From Singapore to Canada: a blueprint for primary care transformation
-
How board certification fuels the physician shortage crisis
-
Recent Posts
-
Why hormonal shifts make traditional dieting ineffective for midlife women [PODCAST]
-
Physician burnout: a poem on the unseen weight of medicine
-
How Medicare’s MIPS impacts skilled nursing facilities and clinicians
-
How to spot artificial intelligence recruiters who target candidates from LinkedIn
-
The truth about Medicare Advantage funding and costs
-
Why symptom variability in chronic illness is not failure
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
